The main objective in this study was to determine how the gene expression profile in CLL primary cells changes after treatment with one of the second-generation MDM2–p53-binding antagonists RG7388 (idasanutlin). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.